# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

# **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2014

# RPX Corporation (Exact name of registrant as specified in its charter)

Delaware	001-35146	26-2990113
(State or other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)
	One Market Plaza	
	Suite 800	
	San Francisco, CA 94105	
(Add	ress of principal executive offices, including zip code)	
	(866) 779-7641	
(R	tegistrant's telephone number, including area code)	
(Forms	er Name or Former Address, if Changed Since Last Rep	out)
Check the appropriate box below if the Form 8-K filing provisions (see General Instruction A.2):		
Written communications pursuant to Rule 425 u	under the Securities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 und	er the Exchange Act (17 CFR 240.14a-12)	
Pre-commencement communications pursuant t	o Rule 14d-2(b) under the Exchange Act (17 CFR	240.14d-2(b))
Pre-commencement communications pursuant t	o Rule 13e-4(c) under the Exchange Act (17 CFR	240.13e-4(c))

#### Item 2.02 Results of Operations and Financial Condition.

On July 29, 2014, RPX Corporation issued a press release announcing its financial results for the second quarter ended June 30, 2014. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release issued by RPX Corporation dated July 29, 2014

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**RPX** Corporation

By: /s/ MARTIN E. ROBERTS

Martin E. Roberts General Counsel

Dated: July 29, 2014



#### **RPX Announces Second Quarter 2014 Financial Results**

SAN FRANCISCO – July 29, 2014 – RPX Corporation (NASDAQ: RPXC), the leading provider of patent risk management solutions, today announced its financial results for the second quarter ended June 30, 2014.

#### **Financial Highlights**

- Subscription revenue for the second quarter of fiscal 2014 was \$64.3 million, up 17% compared to \$55.0 million in the prior year period
- Client count for the second quarter of fiscal 2014 increased by six members bringing our total client network to 184 as of June 30, 2014

"It was another quarter of solid operating results for RPX," said John Amster, President and CEO. "We grew the network, continued building the insurance business and made good progress rolling out our new initiatives."

#### **Summary Results**

Revenue for the second quarter of fiscal 2014 was \$64.3 million, compared to \$57.5 million in the prior year period.

Net acquisition spend during the quarter totaled \$17.8 million, and included 13 new acquisitions of patent assets, in addition to the exercise of previously negotiated options to acquire licenses for new clients.

GAAP net income for the second quarter was \$9.4 million or \$0.17 per diluted share, compared to \$10.7 million or \$0.20 per diluted share in the second quarter of 2013.

Non-GAAP net income for the second quarter, which excludes stock-based compensation and the amortization of acquired intangibles (in each case, net of tax), was \$12.9 million or \$0.24 per pro forma diluted share<sup>[1]</sup>, compared to \$14.0 million or \$0.26 per pro forma diluted share<sup>[1]</sup> in the second quarter of 2013

As of June 30, 2014, RPX had cash, cash equivalents and short-term investments of \$317.6 million.

#### **Business Outlook**

This outlook reflects the Company's current and preliminary view and may be subject to change. Please see the paragraph regarding "Forward-Looking Statements" at the end of this news release.

The Company provided the following business outlook for the third quarter of fiscal 2014:

Subscription revenue <sup>[2]</sup>	\$62.3 - \$63.0 million
Fee-related revenue	\$0.8 million
Total revenue	\$63.1 - \$63.8 million
Net income (non-GAAP)	\$12.0 - \$12.6 million
Effective tax rate (non-GAAP)	37%
Pro forma weighted-average diluted shares outstanding	55.0 million

The Company provided the following business outlook for the full year 2014:

Subscription revenue <sup>[2]</sup>	\$246 - \$258 million
Fee-related revenue	\$8 - \$10 million
Total revenue	\$254 - \$268 million
Cost of revenue (non-GAAP)	\$120 - \$124 million
SG&A (non-GAAP)	\$51 - \$55 million
Net income (non-GAAP)	\$53 - \$57 million
Effective tax rate (non-GAAP)	37%
Pro forma weighted-average diluted shares outstanding	54.6 million
Net acquisition spend	\$135 million

The above outlook is forward-looking. Actual results may differ materially. Please refer to the information under the caption "Use of Non-GAAP Financial Information" below.

#### **Conference Call**

RPX management will host a conference call and live webcast for analysts and investors at 2:00 p.m. PDT/5:00 p.m. EDT on July 29, 2014. Parties in the United States and Canada can access the call by dialing 1-888-572-7025, using conference code 1619659. International parties can access the call by dialing 1-719-325-2454, using conference code 1619659.

RPX will offer a live webcast of the conference call which can be accessed from the "Investor Relations" section of the Company's website at http://ir.rpxcorp.com. An audio replay of the conference call will also be available approximately two hours after the call and will be available for 30 days. To hear the replay, parties in the United States and Canada should call 1-888-203-1112 and enter conference code 1619659. International parties should call 1-719-457-0820 and enter conference code 1619659.

<sup>[1]</sup> Pro forma diluted shares computed to give effect to the shares of restricted stock outstanding as of the original date of issuance.

<sup>[2]</sup> Subscription revenue is comprised of revenue generated from membership subscription services and premiums earned from insurance policies.

#### **About RPX Corporation**

RPX Corporation (NASDAQ: RPXC) is the leading provider of patent risk solutions, offering defensive buying, acquisition syndication, patent intelligence, insurance services and advisory services. Since its founding in 2008, RPX has introduced efficiency to the patent market by providing a rational alternative to litigation. The San Francisco-based company's pioneering approach combines principal capital, deep patent expertise, and client contributions to generate enhanced patent buying power. By acquiring patents and patent rights, RPX helps to mitigate and manage patent risk for its growing client network.

#### **Use of Non-GAAP Financial Information**

This news release dated July 29, 2014 contains non-GAAP financial measures. Tables are provided in this news release that reconcile the non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures include non-GAAP cost of revenue, non-GAAP selling, general and administrative expenses, non-GAAP net income, and non-GAAP net income per share.

To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. Management is excluding from its non-GAAP operating results stock-based compensation expenses (inclusive of related employer payroll taxes), the amortization of acquired intangible assets (other than patents) and related tax effects. Management uses these non-GAAP measures to evaluate the Company's financial results, and believes these non-GAAP measures may prove useful to investors who wish to consider the impact of certain items when comparing the Company's financial performance with that of other companies. The adjustments to the Company's GAAP results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends and performance. The presentation of additional information should not be considered in isolation or as a substitute for or superior to financial results determined in accordance with GAAP.

#### Forward-Looking Statements

This news release and its attachments contain forward-looking statements within the meaning of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements regarding the future financial performance of RPX as well as any statements regarding the Company's strategic and operational plans. The Company's actual results may differ materially from those predicted or implied in these forward-looking statements. Factors that may contribute to such differences include, among others, the Company's ability to maintain an adequate rate of growth, the success of the Company's insurance business and other new initiatives, and the Company's ability to attract new clients and retain existing clients. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "target," "will," "would," and similar expressions or variations intended to identify forward-looking statements. More information about potential factors that could affect the Company's business and financial results is included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent annual report on Form 10-K and its quarterly reports on Form 10-Q on file and available at the SEC's website at www.sec.gov. The Company does not intend, and undertakes no duty, to update any forward-looking statements to reflect future events or circumstances.

# # #

#### **Contacts:**

Investor RelationsMedia RelationsJoAnn HorneLily LohMarket Street PartnersRPX Corporation+1-415-445-3233+1-415-418-2155ir@rpxcorp.commedia@rpxcorp.com

# **Condensed Consolidated Statements of Operations**

# (in thousands, except per share data)

	Three Months Ended June 30,			Six Months Ended June 30,				
		2014		2013		2014		2013
Revenue	\$	64,293	\$	57,481	\$	126,181	\$	118,675
Cost of revenue		31,542		24,694		60,462		48,364
Selling, general and administrative expenses		18,579		15,736		35,834		30,209
(Gain) loss on sale of patent assets, net		(699)		126		(699)		126
Operating income		14,871		16,925		30,584		39,976
Other income, net		94		63		193		114
Income before provision for income taxes		14,965		16,988		30,777		40,090
Provision for income taxes		5,566		6,291		11,518		14,698
Net income	\$	9,399	\$	10,697	\$	19,259	\$	25,392
						40.550		
Net income available to common stockholders:	\$	9,399	\$	10,691	\$	19,259	\$	25,370
Net income available to common stockholders per common share:								
Basic	\$	0.18	\$	0.21	\$	0.36	\$	0.49
Diluted	\$	0.17	\$	0.20	\$	0.35	\$	0.48
Weighted-average shares used in computing net income available to common stockholders per common share:								
Basic		53,203		51,774		53,004		51,489
Diluted		54,776		53,463		54,622		53,055

# **Condensed Consolidated Balance Sheets**

#### (in thousands)

	June 30, 2014		December 31, 2013	
Assets				
Current assets:				
Cash and cash equivalents	\$ 118,	589	\$ 100,155	
Short-term investments	198,	965	190,567	
Restricted cash		583	364	
Accounts receivable	12,	385	38,477	
Prepaid expenses and other current assets	13,	776	10,546	
Deferred tax assets	4,	082	3,817	
Total current assets	348,	380	343,926	
Patent assets, net	235,	501	219,954	
Property and equipment, net	4,	391	4,667	
Intangible assets, net	4,	441	1,718	
Goodwill	19,	978	16,460	
Restricted cash, less current portion	1,	091	1,454	
Other assets		584	622	
Total assets	\$ 614,	366	\$ 588,801	
Liabilities and stockholders' equity				
Current liabilities:				
Accounts payable	\$	343	\$ 332	
Accrued liabilities	8,	442	8,784	
Deferred revenue	129,	009	131,808	
Deferred payment obligations		_	500	
Other current liabilities	4,	418	1,638	
Total current liabilities	142,	212	143,062	
Deferred revenue, less current portion	2,	198	5,935	
Deferred tax liabilities	12,	182	11,654	
Other liabilities	3,	086	3,227	
Total liabilities	159,	678	163,878	
Stockholders' equity:				
Common stock		5	5	
Additional paid-in capital	315,	868	305,343	
Retained earnings	138,	786	119,527	
Accumulated other comprehensive income		29	48	
Total stockholders' equity	454,	688	424,923	
Total liabilities and stockholders' equity	\$ 614,	366	\$ 588,801	

# **Condensed Consolidated Statements of Cash Flows**

# (in thousands)

Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities           Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         —         1,099           Business acquisition, net of cash         (2,169)         —           Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100		Six	Six Months Ended June 30,			
Net income         \$ 19,59 \$ 25,392           Adjustments to reconcile net income to net eash provided by operating activities:         47,798           Depreciation and amortization         59,289 \$ 47,798           Stock-based compensation         8,686 \$ 8,186           Excess tax benefit from stock-based compensation         2,000 \$ (2,000)           (Gain) loss on sale of patent assets         3,380 \$ (2,955)           Amortization of premium on investments         3,380 \$ (2,955)           Deferred taxes         6,078 \$ (1),000           Other         (50,000)         13           Changes in assets and liabilities:         3,300 \$ (2,000)           Changes in assets and liabilities:         3,375 \$ (2,000)         3,375 \$ (2,000)           Other receivable         26,414 \$ (2)6         216           Other receivable         26,414 \$ (2)6         216           Other receivable         3,375 \$ (3,348)         3,300 \$ (3,348)           Accounts payable         11         130           Accident provided by operating activities         82,30 \$ (1),191           Deferred revenue         (6,636) \$ (3,200)           Purchases of investments classified as available-for-sale         9,890 \$ (8,850)           Business acquisition, net of cash         2,109         2,895 <th< th=""><th></th><th>2014</th><th>i</th><th>2013</th></th<>		2014	i	2013		
Adjustments to reconcile net income to net eash provided by operating activities:         59,289         47,788           Depreciation and amortization         8,868         8,186           Stock-based compensation         (2,006)         (2,009)           (Gain) loss on sale of patent assets         (699)         126           Amortization of premium on investments         3,380         2,995           Deferred taxes         (708)         (1,906)           Other         (500)         13           Changes in assets and liabilities:         26,414         216           Other receivables         2         4,114         216           Other receivables         2         4,11         130           Accounts payable         11         13         13           Accounts payable         11         13         13           Accounts payable         (6,636)         13,202           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         82,30         6,8950           Materities of investments classified as available-for-sale         98,920         65,875           Sales of investments classified as available-for-sale         98,920         65,875           Suiteres of investments cla	Cash flows from operating activities					
Depreciation and amortization         59,289         47,798           Stock-based compensation         8,568         8,186           Excess tax benefit from stock-based compensation         (2,006)         (2,009)           (Gain) loss on sale of patent assets         (699)         126           Amortization of premium on investments         3,380         2,995           Deferred taxes         (750)         (1,906)           Other         (500)         13           Changes in assets and liabilities:         26,414         216           Other receivables         26,414         216           Other receivables         26,414         216           Other receivables         26,414         216           Other receivables         26,414         216           Accounts receivable         26,41         216           Accounts payable         11         130           Accrued and other liabilities         (823)         (1,911)           Deferred revenue         (6,656)         13,202           Net cash provided by operating activities         100,305         123,379           Purchases of investments classified as available-for-sale         (106,618)         (89,50)           Muturities of investments classified as available	Net income	\$	19,259 \$	25,392		
Stock-based compensation         8,868         8,186           Excess tax benefit from stock-based compensation         (2,000)         (2,000)           (Gain) loss on sale of patent assets         (699)         126           Amortization of premium on investments         3,380         2,995           Deferred taxes         (978)         (1,906)           Other         (300)         13           Changes in assets and liabilities:         26,414         216           Other receivable         26,414         216           Other receivables         26,414         216           Other receivables         26,241         33,775           Prepaid expenses and other assets         (5,274)         (3,348)           Accounts payable         11         13           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         23,379           Cash flows from investing activities         98,920         65,787           Maturities of investments classified as available-for-sale         (106,618)         98,950           Maturities of investments classified as available-for-sale         (2,169)         —	Adjustments to reconcile net income to net cash provided by operating activities:					
Excess tax benefit from stock-based compensation         (2,009)         (2,009)           (Gain) loss on sale of patent assets         (699)         126           Amortization of premium on investments         3,380         2,995           Deferred taxes         (978)         (1,906)           Other         (500)         13           Changes in assets and liabilities:         26,414         216           Other receivable         26,414         216           Other receivables         -         33,755           Prepaid expenses and other assets         (5,274)         3,348           Accounts payable         11         130           Accounts dand other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         (6,636)         13,202           Purchases of investments classified as available-for-sale         (10,6618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         55,787           Sales of investments classified as available-for-sale         (10,6618)         (98,950)           Maturities of investments classified as available-for-sale         (7,109)         (7,109)           Sales of investments	Depreciation and amortization		59,289	47,798		
(Gain) loss on sale of patent assets         (699)         126           Amortization of premium on investments         3,380         2,995           Deferred taxes         (978)         (1,906)           Other         (500)         133           Changes in assets and liabilities:           Accounts receivable         26,414         216           Other receivables         26,414         216           Other receivables         45,274         (3,348)           Accounts payable         11         130           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities         100,305         123,379           Ruthits of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         10,09         8,950           Sales of investments classified as available-for-sale         2,109         -           Purchases of property and equipment         (2,169)         -           Acquisitions of patent assets         860         100           Proceeds fr	Stock-based compensation		8,868	8,186		
Amortization of premium on investments         3,380         2,995           Deferred taxes         (978)         (1,966)           Other         (500)         13           Changes in assets and liabilities:         Temporary         33,775           Accounts receivable         26,414         216           Other receivables         5,274         33,375           Prepaid expenses and other assets         (5,274)         3,348           Accounts payable         11         130           Accounts due of the isbilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Muturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         106,618         98,950           Muturities of investments classified as available-for-sale         7,009         65,787           Sales of investments classified as available-for-sale         7,009         65,787           Sales of investments classified as available-for-sale         7,009         65,787	Excess tax benefit from stock-based compensation		(2,006)	(2,009)		
Deferred taxes         (978)         (1,906)           Other         (500)         13           Changes in assets and liabilities:         500         13           Accounts receivable         26,414         216           Other receivables         -         33,755           Prepaid expenses and other assets         (5,274)         (3,348)           Accounts payable         11         13           Accound and other liabilities         (83)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Turchases of investments classified as available-for-sale         (106,618)         (98,950)           Muturities of investments classified as available-for-sale         8,950         65,787           Sales of investments classified as available-for-sale         9,890         65,787           Sales of investments classified as available-for-sale         106,618         98,950           Business acquisition, net of cash         (2,169)         -           Decrease in restricted cash         144         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         8,00         10<	(Gain) loss on sale of patent assets		(699)	126		
Other         (500)         13           Changes in assets and liabilities:         26,414         216           Accounts receivable         26,414         216           Other receivables         26,414         33,755           Prepaid expenses and other assets         (5,274)         (3,348)           Accounts payable         11         130           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         23,379           Cash flows from investing activities         100,305         23,379           Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         (106,618)         (98,950)           Business acquisition, net of cash         (2,169)            Decrease in restricted cash         (1,49)            Purchases of property and equipment         (790)         (874)           Acquisitions of patent ase	Amortization of premium on investments		3,380	2,995		
Changes in assets and liabilities:         26,414         216           Other receivables         -         33,775           Prepaid expenses and other assets         (5,274)         (3,348)           Accounts payable         11         130           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         -         100,305         123,379           Cash flows from investing activities         -         100,305         123,379           Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         (2,169)         -           Decrease in restricted cash         (2,169)         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (35,44)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         880	Deferred taxes		(978)	(1,906)		
Accounts receivable         26,414         216           Other receivables	Other		(500)	13		
Other receivables         —         33,775           Prepaid expenses and other assets         (5,274)         (3,348)           Accounts payable         11         130           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities         2         4         4         9,8950           Maturities of investments classified as available-for-sale         98,920         65,787         65,787           Sales of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         -         1,099           Business acquisition, net of cash         (2,169)         -           Decrease in restricted cash         144         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727	Changes in assets and liabilities:					
Prepaid expenses and other assets         (5,274)         (3,348)           Accounts payable         11         130           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities           Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Muturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         -         1,099           Business acquisition, net of cash         (2,169)         -           Decrease in restricted cash         (14         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         2,675         -	Accounts receivable		26,414	216		
Accounts payable         11         130           Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities         100,618         (98,950)           Maturities of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         1,099         -           Business acquisition, net of cash         (2,169)         -         -           Decrease in restricted cash         144         -         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         8,360         100           Proceeds from exercise of stock options and other common stock issuances         2,399         2,727           Excess tax benefit fr	Other receivables		_	33,775		
Accrued and other liabilities         (823)         (1,191)           Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities           Purchases of investments classified as available-for-sale         (106,618)         98,950           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         -         1,099           Business acquisition, net of cash         (2,169)         -           Decrease in restricted cash         144         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         69,637           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         2,675         -           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730	Prepaid expenses and other assets		(5,274)	(3,348)		
Deferred revenue         (6,636)         13,202           Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities         100,618         (98,950)           Purchases of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         -         1,099           Business acquisition, net of cash         (2,169)         -           Decrease in restricted cash         144         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         2,096         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Accounts payable		11	130		
Net cash provided by operating activities         100,305         123,379           Cash flows from investing activities         Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         -         1,099           Business acquisition, net of cash         (2,169)         -           Decrease in restricted cash         144         -           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         -           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         10	Accrued and other liabilities		(823)	(1,191)		
Cash flows from investing activities           Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         —         1,099           Business acquisition, net of cash         (2,169)         —           Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         —           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Deferred revenue		(6,636)	13,202		
Purchases of investments classified as available-for-sale         (106,618)         (98,950)           Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         —         1,099           Business acquisition, net of cash         (2,169)         —           Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         —           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Net cash provided by operating activities	1	00,305	123,379		
Maturities of investments classified as available-for-sale         98,920         65,787           Sales of investments classified as available-for-sale         —         1,099           Business acquisition, net of cash         (2,169)         —           Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         —           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Cash flows from investing activities					
Sales of investments classified as available-for-sale         —         1,099           Business acquisition, net of cash         (2,169)         —           Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         —           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Purchases of investments classified as available-for-sale	(1	06,618)	(98,950)		
Business acquisition, net of cash         (2,169)         —           Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         —           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Maturities of investments classified as available-for-sale		98,920	65,787		
Decrease in restricted cash         144         —           Purchases of property and equipment         (790)         (874)           Acquisitions of patent assets         (73,948)         (69,637)           Proceeds from sale of patent assets         860         100           Net cash used in investing activities         (83,601)         (102,475)           Cash flows from financing activities         2,399         2,727           Tax withholdings related to net share settlements of restricted stock units         (2,675)         —           Excess tax benefit from stock-based compensation         2,006         2,009           Net cash provided by financing activities         1,730         4,736           Net increase in cash and cash equivalents         18,434         25,640           Cash and cash equivalents at beginning of period         100,155         73,638	Sales of investments classified as available-for-sale		_	1,099		
Purchases of property and equipment(790)(874)Acquisitions of patent assets(73,948)(69,637)Proceeds from sale of patent assets860100Net cash used in investing activities(83,601)(102,475)Cash flows from financing activities2,3992,727Tax withholdings related to net share settlements of restricted stock units(2,675)—Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Business acquisition, net of cash		(2,169)	_		
Acquisitions of patent assets Proceeds from sale of patent assets Net cash used in investing activities  Cash flows from financing activities Proceeds from exercise of stock options and other common stock issuances Proceeds from exercise of stock options and other common stock issuances  Tax withholdings related to net share settlements of restricted stock units  Excess tax benefit from stock-based compensation Net cash provided by financing activities  Net increase in cash and cash equivalents  Cash and cash equivalents at beginning of period  (69,637) (69,637) (69,637) (69,637) (73,948) (69,637) (69,637) (73,948) (69,637) (69,637) (73,948) (69,637) (69,637) (73,948) (69,637) (69,637) (73,948) (69,637) (73,948) (69,637) (73,948) (69,637) (73,948) (69,637) (73,948) (69,637) (73,948) (69,637) (73,948) (69,637) (73,948) (100,475)	Decrease in restricted cash		144	_		
Proceeds from sale of patent assets860100Net cash used in investing activities(83,601)(102,475)Cash flows from financing activitiesProceeds from exercise of stock options and other common stock issuances2,3992,727Tax withholdings related to net share settlements of restricted stock units(2,675)—Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Purchases of property and equipment		(790)	(874)		
Net cash used in investing activities(83,601)(102,475)Cash flows from financing activitiesTotal cash grow exercise of stock options and other common stock issuances2,3992,727Proceeds from exercise of stock options and other common stock issuances(2,675)—Excess tax withholdings related to net share settlements of restricted stock units(2,675)—Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Acquisitions of patent assets	(	(73,948)	(69,637)		
Cash flows from financing activitiesProceeds from exercise of stock options and other common stock issuances2,3992,727Tax withholdings related to net share settlements of restricted stock units(2,675)—Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Proceeds from sale of patent assets		860	100		
Proceeds from exercise of stock options and other common stock issuances2,3992,727Tax withholdings related to net share settlements of restricted stock units(2,675)—Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Net cash used in investing activities	(	83,601)	(102,475)		
Tax withholdings related to net share settlements of restricted stock units(2,675)—Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Cash flows from financing activities					
Excess tax benefit from stock-based compensation2,0062,009Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Proceeds from exercise of stock options and other common stock issuances		2,399	2,727		
Net cash provided by financing activities1,7304,736Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Tax withholdings related to net share settlements of restricted stock units		(2,675)	_		
Net increase in cash and cash equivalents18,43425,640Cash and cash equivalents at beginning of period100,15573,638	Excess tax benefit from stock-based compensation		2,006	2,009		
Cash and cash equivalents at beginning of period 100,155 73,638	Net cash provided by financing activities		1,730	4,736		
Cash and cash equivalents at beginning of period 100,155 73,638	Net increase in cash and cash equivalents		18,434	25,640		
	•					

# Reconciliation of Pro Forma Net Income Per Share (in thousands, except per share data)

(unaudited)

	Three Months Ended June 30,			Six Months Ended June 30,				
		2014		2013		2014		2013
Net income	\$	9,399	\$	10,697	\$	19,259	\$	25,392
Pro forma net income per share:								
Basic	\$	0.18	\$	0.21	\$	0.36	\$	0.49
Diluted	\$	0.17	\$	0.20	\$	0.35	\$	0.48
Shares used in computing pro forma net income per share:								
Basic:								
Basic weighted-average common shares		53,203		51,774		53,004		51,489
Add: Restricted stock		_		31		_		45
Shares used in computing pro forma basic net income per share		53,203		51,805		53,004		51,534
Diluted:								
Diluted weighted-average common shares		54,776		53,463		54,622		53,055
Add: Restricted stock		_		31		_		45
Shares used in computing pro forma diluted net income per share		54,776		53,494		54,622		53,100

# RPX Corporation Reconciliation of GAAP to Pro Forma Non-GAAP Net Income Per Share (in thousands, except per share data)

	Three Months Ended June 30,			Six Months Ended June 30,				
		2014		2013		2014		2013
Net income	\$	9,399	\$	10,697	\$	19,259	\$	25,392
Stock-based compensation <sup>[1]</sup>		5,162		4,658		9,081		8,436
Amortization of acquired intangible assets <sup>[2]</sup>		257		358		562		718
Income tax adjustments <sup>[3]</sup>		(1,873)		(1,676)		(3,242)		(2,961)
Non-GAAP net income	\$	12,945	\$	14,037	\$	25,660	\$	31,585
Pro forma non-GAAP net income per share:	_							
Basic	\$	0.24	\$	0.27	\$	0.48	\$	0.61
Diluted	\$	0.24	\$	0.26	\$	0.47	\$	0.59
Shares used in computing pro forma net income per share:								
Basic		53,203		51,805		53,004		51,534
Diluted		54,776		53,494		54,622		53,100

# Reconciliation of GAAP to Non-GAAP Cost of Revenue

#### (in thousands)

(unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,				
		2014		2013		2014		2013	
Cost of revenue	\$	31,542	\$	24,694	\$	60,462	\$	48,364	
Amortization of acquired intangible assets <sup>[2]</sup>		(47)		(56)		(103)		(112)	
Non-GAAP cost of revenue	\$	31,495	\$	24,638	\$	60,359	\$	48,252	

# RPX Corporation

# Reconciliation of GAAP to Non-GAAP Selling, General and Administrative Expenses

(in thousands)

	Three Months Ended June 30,					Six Months Ended June 30,					
		2014		2013		2014		2013			
Selling, general and administrative expenses	\$	18,579	\$	15,736	\$	35,834	\$	30,209			
Stock-based compensation <sup>[1]</sup>		(5,162)		(4,658)		(9,081)		(8,436)			
Amortization of acquired intangible assets <sup>[2]</sup>		(210)		(302)		(459)		(606)			
Non-GAAP selling, general and administrative expenses	\$	13,207	\$	10,776	\$	26,294	\$	21,167			

#### **Additional Metrics**

#### (in thousands, except client and headcount data)

(unaudited)

As of and for the Three Months Ended

\$

131,207

\$

117,573

June 30, **Operating Metrics** 2014 2013 Number of clients 157 184 Net additions 6 11 Trailing four quarters 27 37 \$ 18,795 41,100 Gross acquisition spend \$ Trailing four quarters \$ 139,162 \$ 201,273 \$ 17,795 \$ 39,100 Net acquisition spend \$ 131,412 \$ 118,073 Trailing four quarters Full time equivalent headcount 138 123 As of and for the Three Months Ended June 30, 2013 **Financial Metrics** 2014 \$ Subscription revenue<sup>[4]</sup> \$ 64,293 54,979 Fee-related revenue 2,502 \$ 64,293 Total revenue \$ 57,481 \$ Cash, cash equivalents and short-term investments 317,554 \$ 259,305

Deferred revenue, current and noncurrent

<sup>[1]</sup> RPX excludes stock-based compensation and related employer payroll taxes from its non-GAAP financial measures.

<sup>[2]</sup> RPX excludes amortization expense related to intangible assets (other than patents) acquired in conjunction with the acquisition of businesses from its non-GAAP financial measures.

<sup>[3]</sup> Amount reflects income taxes associated with the above noted non-GAAP exclusions.
[4] Subscription revenue is comprised of revenue generated from membership subscription services and premiums earned from insurance policies.